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Abstract
 Background—Receiving a healthcare provider’s recommendation is a strong predictor of 
HPV vaccination, but little is known empirically about which types of recommendation are most 
influential. Thus, we sought to investigate the relationship between recommendation quality and 
HPV vaccination among U.S. adolescents.
 Methods—In 2014, we conducted a national, online survey of 1,495 parents of 11- to 17-year-
old adolescents. Parents reported whether providers endorsed HPV vaccination strongly, 
encouraged same-day vaccination, and discussed cancer prevention. Using an index of these 
quality indicators, we categorized parents as having received no, low-quality, or high-quality 
recommendations for HPV vaccination. Separate multivariable logistic regression models assessed 
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associations between recommendation quality and HPV vaccine initiation (≥1 dose), follow 
through (3 doses, among initiators), refusal, and delay.
 Results—Almost half (48%) of parents reported no provider recommendation for HPV 
vaccination, while 16% received low-quality recommendations and 36% received high-quality 
recommendations. Compared to no recommendation, high-quality recommendations were 
associated with over nine times the odds of HPV vaccine initiation (23% vs. 74%, OR=9.31, 95% 
CI, 7.10–12.22) and over three times the odds of follow through (17% vs. 44%, OR=3.82, 95% CI, 
2.39–6.11). Low-quality recommendations were more modestly associated with initiation 
(OR=4.13, 95% CI, 2.99–5.70), but not follow through. Parents who received high-versus low-
quality recommendations less often reported HPV vaccine refusal or delay.
 Conclusions—High-quality recommendations were strongly associated with HPV 
vaccination behavior, but only about one-third of parents received them. Interventions are needed 
to improve not only whether, but how providers recommend HPV vaccination for adolescents.
Keywords
adolescent health; human papillomavirus infections/prevention & control; human papillomavirus 
vaccine; health communication; quality of health care
 INTRODUCTION
Only a small minority of adolescents in the United States receives human papillomavirus 
(HPV) vaccine according to national guidelines. Although the Advisory Committee on 
Immunization Practices recommends completion of the three-dose HPV vaccine series by 
age 12, just 26% of females and 12% of males were up-to-date at age 13 in 2013.[1–2] 
Coverage estimates for series completion in older adolescents were somewhat higher, 
reaching 48% for females and 15% for males by age 17, but remain far below the Healthy 
People 2020 goal of 80%.[2,3] These low levels of coverage represent a missed opportunity 
to prevent 53,000 future cervical cancer cases over the lifetimes of today’s population of 
girls ages 12 and younger, as well as many additional cases of other cancers, precancers, and 
genital warts in both sexes.[4]
The urgent need to improve HPV vaccination coverage has generated support for 
immunization quality improvement efforts across a broad array of leaders in adolescent 
health and cancer prevention, including the Centers for Disease Control and Prevention 
(CDC), the President’s Cancer Panel, and the American Academy of Pediatrics.[4–6] A 
consistent theme in this work is the need to increase the frequency with which healthcare 
providers recommend HPV vaccine. [4–6] A provider’s recommendation is so highly 
influential that over 70% of adolescents who receive a recommendation initiate HPV 
vaccination.[7] In relative terms, receiving a provider recommendation is a stronger 
predictor of HPV vaccination than other commonly studied factors, including race/ethnicity, 
insurance status, HPV-related knowledge, or perceptions of HPV vaccine effectiveness and 
safety.[8–11] Despite strong evidence of providers’ influence, more than one-third of age-
eligible girls and half of age-eligible boys do not receive recommendations for HPV 
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vaccination.[12] Taken together, these data make increasing the frequency of provider 
recommendations a logical goal for HPV vaccination quality improvement efforts.
In contrast to recommendation frequency, the role that recommendation quality plays in 
HPV vaccination is less clear. A growing body of research suggests that, in addition to being 
infrequent, providers’ recommendations for HPV vaccination are often weak insofar as they 
frame HPV vaccine as less important than other vaccines or suggest deferring HPV 
vaccination to a future visit.[13–16] Furthermore, parents who perceive providers’ 
recommendations as weak may be less likely to get HPV vaccine for their children.[17–18] 
In response to these concerns, the CDC encourages providers to deliver “strong” 
recommendations for HPV vaccination. More specifically, educational materials for 
healthcare providers suggest strategies such as saying the vaccine is important, emphasizing 
cancer prevention, and encouraging same-day vaccination.[19] Although these suggestions 
hold intuitive appeal and were informed by formative research, little is known empirically 
about how to define a strong recommendation or its relative influence on HPV vaccination 
behavior.
To address this gap, we used data from a national survey to evaluate the quality of 
recommendations that parents of adolescents received for HPV vaccination on three factors: 
strength of endorsement, prevention message, and urgency. We assessed associations 
between provider recommendation quality and four HPV vaccination behaviors: initiation 
(≥1 dose), follow through (3 doses, among initiators), refusal, and delay. Finally, we sought 
to identify disparities in recommendation quality across key demographic characteristics. By 
providing novel data on the role of recommendation quality, our study seeks to inform the 
many state and national campaigns aimed at improving provider communication so as to 
increase HPV vaccination coverage in the U.S.
 METHODS
 Participants and procedures
We conducted an online survey of parents of adolescents in November 2014 to January 
2015. Respondents were members of a standing panel of U.S. adults maintained by a survey 
research company.[20] To construct a nationally-representative panel, the company used a 
probability-based sampling approach consisting of list-assisted, random-digit dialing 
supplemented by address-based sampling to provide coverage of households without 
telephones.[20] Eligible respondents were parents of an 11- to 17-year-old child. Parents 
received a computer and free internet access or points toward small cash payments as 
incentives for their ongoing participation in the study panel.
The survey company emailed invitations to 2,845 parents selected from the panel using a 
probability proportional to size (PPS) weighted sampling approach. A total of 1,760 parents 
responded by visiting the survey website, completing an eligibility screener as to whether 
they were the parent of an age-eligible child, and providing informed consent. Of these, 
1,504 parents met eligibility criteria and went on to complete the survey. Using the 
American Association for Public Opinion Research guidelines for Response Rate 5,[21] we 
calculated an overall response rate of 61%.We excluded respondents who did not provide 
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data on key variables (n=9) for a final analytic sample of 1,495 parents. The University of 
North Carolina Institutional Review Board approved the study protocol.
 Measures
Our survey assessed receipt of provider recommendation with one item: “Has a doctor or 
other healthcare provider ever told you [NAME] should get the HPV vaccine?”[22] For 
parents who indicated yes, the survey assessed three recommendation quality indicators that 
we identified based on the research literature and CDC recommendations for communicating 
about HPV vaccine.[16,19] Based on evidence that some providers frame HPV vaccine as an 
optional vaccine,[14–15] we assessed strength of endorsement, or whether the provider said 
HPV vaccine was “very” or “extremely” important. Because parents value the opportunity to 
prevent HPV-attributable cancers,[19] we assessed prevention message, or whether the 
provider said HPV vaccine prevents cancer. Because some providers suggest delaying HPV 
vaccination to a later visit,[14–15] we assessed urgency, or whether the provider 
recommended same-day vaccination. We combined these three items into an index of overall 
recommendation quality by awarding one point for each indicator of quality, calculating the 
sum, and creating two categories: low-quality recommendation (scores of 0–1) and high-
quality recommendation (scores of 2–3).
Our survey assessed HPV vaccination status with one item: “How many shots of the HPV 
vaccine has [NAME] had?”[23] We defined HPV vaccine initiation as responses of 1 or 
more shots. We defined HPV vaccine follow through as responses of 3 shots, among those 
children who had initiated the series. We adopted the concept of follow through from Reiter 
and colleagues, who note that, unlike series completion, the measure has the advantage of 
focusing specifically on the behavior of continuing the vaccine series once it is started. [24]
Our survey assessed HPV vaccine refusal and delay with two items: “Has there ever been a 
time when you [refused or decided not to get/delayed or put off getting] the HPV vaccine for 
[NAME]?” Refusal and delay items used yes/no response options. We adapted these items 
from measures used on the 2010 National Immunization Survey (NIS) – Teen. [25]
On demographic characteristics, our survey assessed the sex, age, and race/ethnicity of the 
index child. The survey company provided data on parents’ sex and educational attainment. 
For each household, the company also provided data on annual income and location of 
residence in terms of U.S. state and national region.
Prior to fielding, we cognitively tested and pretested our survey to assess respondent 
comprehension and ensure proper functioning. The full survey instrument is available online 
at http://www.unc.edu/~ntbrewer/2014_pharmacy.pdf.
 Statistical analysis
We used multivariable logistic regression to assess associations between HPV vaccine 
recommendation quality and HPV vaccination behavior. Using separate models, we first 
assessed associations between each recommendation quality indicator and HPV vaccine 
initiation; we then assessed the association between overall quality and initiation. We 
repeated these analyses for the outcomes of HPV vaccine follow through, refusal, and delay. 
Gilkey et al. Page 4
Vaccine. Author manuscript; available in PMC 2017 February 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Models controlled for five demographic variables that correlate with HPV vaccination 
behavior: child’s sex, child’s age, child’s race/ethnicity, parent’s educational attainment, and 
annual household income.[2,8,26–27] We used Pearson’s chi-squared tests to assess 
potential disparities in HPV vaccine recommendation quality across each of these five 
demographic variables.
To assess the robustness of our findings, we repeated analyses after re-categorizing “high-
quality” recommendations to be those with a score of 3 on the recommendation quality 
index (versus a score of 2 or higher as described earlier). Because these analyses yielded a 
similar pattern of findings, we do not report on them further. We conducted analyses using 
Stata Version 12.0 (College Station, TX). Statistical tests were two-tailed with a critical 
alpha of 0.05.
 RESULTS
 Sample characteristics
The sample was balanced with regard to the sex of index children, with 51% of parents 
reporting on a son and 49% reporting on a daughter (Table 1). The mean age for children 
was 14 years, and most were non-Hispanic white (65%), Hispanic (17%), or non-Hispanic 
black (10%). Overall, almost half (46%) had initiated HPV vaccination, with sex-specific 
coverage being 52% for girls and 40% for boys. Among the 689 adolescents who had 
initiated HPV vaccination, 234 (or 34%) had followed through to complete the 3-dose series. 
About one-fifth of parents (22%) reported having a household income of less than $35,000 
per year.
 HPV vaccine recommendation quality
About half of parents (781/1,495 or 52%) in our sample reported receiving a provider 
recommendation for HPV vaccination. Among these 781 respondents, HPV vaccine 
recommendation quality was most often lacking on urgency, with only 317 parents (41%) 
reporting that their child’s provider recommended same-day vaccination (Table 2). On 
strength of endorsement, 495 parents, or 63% of those who received a recommendation, 
indicated that the provider said HPV vaccine was highly important for their child. On 
prevention message, 673 parents, or 86% of those who received a recommendation, reported 
that the provider said HPV vaccine prevents cancer. Using composite recommendation 
quality scores, we categorized parents in our sample as having received no provider 
recommendation for HPV vaccine (48%), a low-quality recommendation (16%), or a high-
quality recommendation (36%).
 Associations between recommendation quality and HPV vaccination behavior
 Initiation—Higher recommendation quality correlated with HPV vaccine initiation 
(Table 3). In terms of overall quality, receiving a high-quality recommendation versus no 
recommendation was associated with over nine times the odds of having received at least 
one dose of HPV vaccine (23% versus 74%, odds ratio [OR]=9.31, 95% confidence interval 
[CI], 7.10–12.22). Receiving a low-quality recommendation versus no recommendation was 
associated with over four times the odds of initiation (23% versus 53%, OR=4.13, 95% CI, 
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2.99–5.70). In indicator-specific models, strength of endorsement was associated with 
initiation, while the association between urgency and initiation approached, but did not 
achieve, statistical significance.
 Follow through—Among children who had initiated HPV vaccination, receiving a 
high-quality recommendation versus no recommendation was associated with following 
through to complete the three-dose series (OR=3.82, 95% CI, 2.39–6.11) (Table 3). 
Receiving a low-quality recommendation approached, but did not achieve, a statistically 
significant association with follow-through. In indicator-specific models, both strength of 
endorsement and prevention message were associated with follow through, while the 
association between urgency and follow through approached statistical significance.
 Refusal and delay—Among parents who had received a recommendation for HPV 
vaccine, higher recommendation quality was associated with less HPV vaccine refusal and 
delay (Table 4). Parents who received a high- versus low-quality recommendation had about 
half the odds of reporting HPV vaccine refusal (OR=0.52, 95% CI, 0.38–0.72) or delay 
(OR=0.59, 95% CI, 0.43–0.82). In indicator-specific models, only strength of endorsement 
was associated with refusal and delay.
 Disparities in recommendation quality
Disparities were present in HPV vaccine recommendation quality by child’s sex and age 
(both p<0.001). Parents less often reported receiving high-quality recommendations for male 
versus female children (29% and 45%, respectively) and for younger children, ages 11–12, 
versus older children, ages 13–15 or 16–17 (28%, 40%, and 39%, respectively) (Figure). 
Conversely, receiving no recommendation was more common for male versus female 
children (56% and 39%), and for ages 11–12 versus ages 13–15 or 16–17 (57%, 44%, and 
45%). The proportion of low-quality recommendations was the same for male and female 
children (16% and 16%) and for ages 11–12, 13–15, and 16–17 (16%, 16%, and 16%). We 
did not find evidence of disparities in recommendation quality by child’s race/ethnicity, 
parent’s educational attainment, or annual household income (all p>0.05).
 DISCUSSION
In a national survey of parents of adolescents, we found that provider recommendation 
quality was consistently associated with HPV vaccination behavior. In keeping with prior 
research,[12,28] almost half of the parents in our sample had not received an HPV vaccine 
recommendation for their age-eligible child, and less than one-quarter of the children in this 
group had initiated HPV vaccination. By contrast, over half of parents who received low-
quality recommendations had initiated HPV vaccination, and about one-quarter of initiators 
followed through with series completion. Even more dramatically, almost three-quarters of 
parents who received high-quality recommendations had initiated HPV vaccination, and well 
over one-third of initiators completed the series. This pattern of findings suggests that high-
quality recommendations may be more effective than low-quality recommendations for 
promoting HPV vaccine initiation and completion.
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Our findings also raise the possibility that high-quality recommendations encourage 
vaccination among vaccine hesitant parents. Parents who received high- versus low-quality 
recommendations less often reported HPV vaccine refusal or delay. While we interpret our 
results with care to acknowledge this study’s cross-sectional design, high-quality 
recommendations may reassure parents and decrease their decisional burden by more clearly 
communicating the recommended course of action. [13] These findings offer early evidence 
to assuage the concern held by some providers that strong recommendations will elicit 
resistance from parents and are therefore best avoided. [13–14]
In terms of implications for improving provider communication, our findings offer support 
for the practices of endorsing HPV vaccine highly, emphasizing cancer prevention, and 
recommending same-day vaccination. Of our three quality indicators, strength of 
endorsement was most consistently associated with HPV vaccination behavior, suggesting 
that this communication practice is especially important. Unfortunately, over one-third of 
parents in our sample reported that their providers did not say HPV vaccination was very 
important for their children, a finding which corresponds to our prior research with 
healthcare providers. For example, in a survey of primary care physicians, we found that 
about one-quarter did not recommend HPV vaccine as being very important for their 11- to 
12-year-old patients. [16]
We found evidence of disparities in who receives high-quality provider recommendations, 
such that parents of younger adolescents and male adolescents less often reported getting 
them. With regard to age, these findings are consistent with prior studies in which healthcare 
providers have expressed a preference for recommending HPV vaccination for older 
adolescents rather than the 11- to 12-year-old age group specified by national guidelines. 
[13–16] With regard to sex, the lack of high-quality recommendations for boys likely 
reflects the history of practice guidelines, which initially recommended routine 
administration of HPV vaccine for girls only. [1] Interventions to improve provider 
communication about HPV vaccination should seek to address disparities in 
recommendation quality by emphasizing the benefits of guideline-consistent delivery of 
HPV vaccine. For male patients, these benefits include the prevention of genital warts and 
HPV-attributable cancers, including anal and oropharyngeal cancers, which are increasingly 
common. [1] For younger patients, benefits include the opportunity to vaccinate before 
exposure and to achieve stronger immune response, which may increase vaccine 
effectiveness. [1,29]
In terms of opportunities for future study, researchers should seek to expand our 
understanding of what constitutes “strong” communication about HPV vaccination. We 
developed our framework of recommendation quality based on national practice guidelines 
and CDC educational materials, [1,5] but other communication practices may be relevant as 
well. For example, in our physician survey, we also explored recommendation “consistency” 
(i.e., using routine- versus risk-based approaches to recommending HPV vaccine) and 
“timeliness” (i.e., recommending HPV vaccine at ages 11 and 12 versus older). [16] 
Investigating subgroup differences is another promising avenue for future research, given 
that the relationship between recommendation quality and HPV vaccination behavior may 
differ according to factors such as adolescents’ sex. Finally, additional research is needed to 
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understand how providers tailor their communication practices according to their 
perceptions of parents’ communication needs. By identifying how and for whom provider 
communication is most influential, future research can offer providers specific guidance 
about how to improve their HPV vaccine recommendations.
Strengths of this study include the use of cognitively tested survey items, a good response 
rate, and a large, national sample of respondents. Correspondence between our findings and 
those of other, nationally-representative surveys provides support for the validity of our 
sample. For example, our estimates of the proportions of 13- to 17-year-old adolescents who 
received provider recommendations for HPV vaccination were similar to those reported by 
the 2013 NIS-Teen for girls (65% vs 64%) and boys (46% vs 42%). [12]
The primary limitation of this study is its cross-sectional design, which prevents us from 
assessing the directionality of the relationship between recommendation quality and HPV 
vaccination behavior. Although our findings are consistent with the hypothesis that 
recommendation quality encourages vaccination, it may also be that parents who vaccinate 
their children are more likely to remember and report higher quality recommendation 
practices. The self-reported nature of our measures is also a limitation, particularly given 
that what constitutes a provider recommendation is not always straightforward. For example, 
parents receiving “presumptive” recommendations, which do not actively engage parents in 
decision making, may not have recognize them as such, leading to misclassification. [30] 
Although parental recall of HPV vaccination is fairly accurate, [31] some parents may have 
also misreported their children’s vaccination status. Finally, because our sample included 
11- to 12-year-olds in the target age range for routine HPV vaccination, some parents may 
not have had an opportunity to discuss HPV vaccination with their children’s healthcare 
providers at the time of the survey. Future research can overcome these limitations by 
employing experimental designs that manipulate provider communication and assess 
subsequent vaccination behavior using medical records.
 Conclusion
The possibility of improving HPV vaccine delivery and, in turn, preventing HPV-attributable 
cancers simply by changing what healthcare providers say has been a cause for considerable 
optimism in recent years, motivating large-scale immunization quality improvement efforts. 
A strong body of evidence speaks to the importance of increasing the frequency of provider 
recommendations for HPV vaccination. The findings of our study provide empirical support 
for the hypothesis that recommendation quality may also influence HPV vaccination 
behavior. By endorsing HPV vaccine highly, recommending same-day vaccination, and 
emphasizing cancer prevention, providers may be able to promote HPV vaccine initiation 
and completion while discouraging vaccine refusal and delay. Future research should seek to 
build on the present study by identifying other discrete communication practices that support 
HPV vaccination and by prospectively assessing their relative influence. By expanding our 
conceptualization of “provider recommendation” from a dichotomous, yes-or-no variable to 
a more complex concept encompassing multiple communication practices, we can arrive at a 
more nuanced understanding of how to communicate effectively about HPV vaccination and 
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other healthcare services that are of vital importance to the goals of cancer prevention and 
control.
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Highlights
• We conducted a national survey of 1,495 U.S. parents of adolescents, 
ages 11–17.
• Parents reported on healthcare provider recommendations for HPV 
vaccination.
• High-quality recommendations were positively associated with HPV 
vaccine uptake.
• High-quality recommendations were negatively associated with refusal 
and delay.
• Only about one-third of parents received high-quality 
recommendations.
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Figure. 
Disparities in receipt of a high-quality recommendation for HPV vaccination (n=1,495). 
Error bars show 95% confidence intervals.
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Table 1
Sample characteristics (n=1,495).
n (%)
Child characteristics
  Sex
    Male 761 (51)
    Female 734 (49)
  Age (years)
    11–12 421 (28)
    13–15 626 (42)
    16–17 448 (30)
  Race/ethnicity
    Non-Hispanic white 979 (65)
    Non-Hispanic black 145 (10)
    Hispanic 260 (17)
    Other 111 (7)
  HPV vaccination status
    0 doses 806 (54)
    ≥1 dose 689 (46)
Parent characteristics
  Sex
    Male 664 (44)
    Female 831 (56)
  Educational attainment
    High school degree or less 575 (38)
    Some college, no degree 388 (26)
    College degree or more 532 (36)
Household characteristics
  Annual income
    <$35,000 328 (22)
    $35,000–$74,999 468 (31)
    ≥$75,000 699 (47)
  Region
    Northeast 260 (17)
    Midwest 391 (26)
    South 494 (33)
    West 350 (23)
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Table 2
Quality of HPV vaccine recommendations received by parents of adolescents.
n (%)
Strength of endorsement
  Provider said HPV vaccine was…
    Not/slightly/moderately important 286 (37)
    Very/extremely important 495 (63)
Prevention message
  Provider said HPV vaccine prevents cancer
    No 108 (14)
    Yes 673 (86)
Urgency
  Provider recommended getting HPV vaccine…
    At later visit/gave a choice/other 464 (59)
    At current visit 317 (41)
Overall quality
  No recommendation 714 (48)
  Low-quality 237 (16)
  High-quality 544 (36)
Note. Individual quality indicators were assessed for parents who received a provider recommendation (n=781). For each indicator, the lower 
quality response is listed first. Overall quality was assessed for all parents (n=1,495).
HPV: human papillomavirus.
Vaccine. Author manuscript; available in PMC 2017 February 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gilkey et al. Page 15
Ta
bl
e 
3
A
ss
oc
ia
tio
ns
 b
et
w
ee
n 
H
PV
 v
ac
ci
ne
 re
co
m
m
en
da
tio
n 
qu
al
ity
 a
nd
 H
PV
 v
ac
ci
ne
 in
iti
at
io
n 
an
d 
fo
llo
w
 th
ro
ug
h.
Pa
re
n
ts
 r
ep
or
tin
g
H
PV
 v
a
cc
in
e
in
iti
at
io
n 
fo
r 
ch
ild
 /
To
ta
l p
ar
en
ts
 in
ca
te
go
ry
 (%
)
M
ul
tiv
a
ri
ab
le
Pa
re
n
ts
 r
ep
or
tin
g
H
PV
 v
a
cc
in
e 
fo
llo
w
th
ro
u
gh
 fo
r 
ch
ild
 /
To
ta
l p
ar
en
ts
 in
ca
te
go
ry
 (%
)
M
ul
tiv
a
ri
ab
le
O
R
(95
%
 C
I)a
O
R
(95
%
 C
I)b
St
ro
ng
 e
nd
or
se
m
en
t
 
 
N
o
15
4/
28
6
(54
)
1
46
/1
54
(30
)
1
 
 
Ye
s
37
2/
49
5
(75
)
2.
58
(1.
86
–3
.56
)**
16
1/
37
2
(43
)
1.
81
(1.
20
–2
.74
)**
Pr
ev
en
tio
n 
m
es
sa
ge
 
 
N
o
74
/1
08
(69
)
1
18
/7
4
(24
)
1
 
 
Ye
s
45
2/
67
3
(67
)
0.
86
(0.
53
–1
.39
)
18
9/
45
2
(42
)
1.
98
(1.
09
–3
.59
)*
U
rg
en
cy
 
 
N
o
29
5/
46
4
(64
)
1
10
5/
29
5
(36
)
1
 
 
Ye
s
23
1/
31
7
(73
)
1.
35
(0.
97
–1
.86
)
10
2/
23
1
(44
)
1.
41
(0.
97
–2
.03
)
O
ve
ra
ll 
qu
al
ity
 
 
N
o 
re
co
m
m
en
da
tio
n
16
3/
71
4
(23
)
1
27
/1
63
(17
)
1
 
 
Lo
w
-q
ua
lit
y
12
6/
23
7
(53
)
4.
13
(2.
99
–5
.70
)**
33
/1
26
(26
)
1.
78
(0.
99
–3
.20
)
 
 
H
ig
h-
qu
al
ity
40
0/
54
4
(74
)
9.
31
(7.
10
–1
2.2
2)*
*
17
4/
40
0
(44
)
3.
82
(2.
39
–6
.11
)**
N
ot
e:
 
M
od
el
s c
on
tro
l f
or
 c
hi
ld
’s
 se
x
, 
ch
ild
’s
 a
ge
, c
hi
ld
’s
 ra
ce
/e
th
ni
ci
ty
,
 
pa
re
nt
’s
 e
du
ca
tio
na
l a
tta
in
m
en
t, 
an
d 
an
nu
al
 h
ou
se
ho
ld
 in
co
m
e.
H
PV
: 
hu
m
an
 p
ap
ill
om
av
iru
s. 
O
R:
 o
dd
s r
at
io
. C
I: 
co
nf
id
en
ce
 in
te
rv
al
.
a O
dd
s o
f r
ec
ei
v
in
g 
at
 le
as
t o
ne
 d
os
e 
of
 H
PV
 v
ac
ci
ne
. A
na
ly
se
s o
f i
nd
iv
id
ua
l q
ua
lit
y 
in
di
ca
to
rs
 re
str
ic
te
d 
to
 p
ar
en
ts 
w
ho
 re
ce
iv
ed
 a
 p
ro
v
id
er
 re
co
m
m
en
da
tio
n 
(n=
78
1).
 O
ve
ra
ll 
qu
al
ity
 a
ss
es
se
d 
fo
r a
ll 
pa
re
nt
s 
(n=
1,
49
5).
b O
dd
s o
f r
ec
ei
v
in
g 
th
re
e 
do
se
s o
f H
PV
 v
ac
ci
ne
, a
m
on
g 
th
os
e 
w
ho
 st
ar
te
d 
th
e 
se
rie
s. 
A
na
ly
se
s o
f i
nd
iv
id
ua
l q
ua
lit
y 
in
di
ca
to
rs
 re
str
ic
te
d 
to
 p
ar
en
ts 
w
ho
 re
ce
iv
ed
 a
 p
ro
v
id
er
 re
co
m
m
en
da
tio
n 
(n=
52
6).
 O
ve
ra
ll 
qu
al
ity
 a
ss
es
se
d 
fo
r a
ll 
pa
re
nt
s w
ho
 st
ar
te
d 
th
e 
se
rie
s (
n
=
68
9).
*
p 
<
 0
.0
5,
*
*
p 
<
 0
.0
1
Vaccine. Author manuscript; available in PMC 2017 February 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gilkey et al. Page 16
Ta
bl
e 
4
A
ss
oc
ia
tio
ns
 b
et
w
ee
n 
H
PV
 v
ac
ci
ne
 re
co
m
m
en
da
tio
n 
qu
al
ity
 a
nd
 H
PV
 v
ac
ci
ne
 re
fu
sa
l a
nd
 d
el
ay
.
Pa
re
n
ts
 r
ep
or
tin
g
H
PV
 v
a
cc
in
e
re
fu
sa
l f
o
r 
ch
ild
 /
To
ta
l p
ar
en
ts
 in
ca
te
go
ry
 (%
)
M
ul
tiv
a
ri
ab
le
Pa
re
n
ts
 r
ep
or
tin
g
H
PV
 v
a
cc
in
e
de
la
y 
fo
r 
ch
ild
 /
To
ta
l p
ar
en
ts
 in
ca
te
go
ry
 (%
)
M
ul
tiv
a
ri
ab
le
O
R
(95
%
 C
I)a
O
R
(95
%
 C
I)b
St
ro
ng
 e
nd
or
se
m
en
t
 
 
N
o
14
7/
28
5
(52
)
1
13
8/
28
4
(49
)
1
 
 
Ye
s
13
8/
49
4
(28
)
0.
37
(0.
27
–0
.50
)**
14
0/
49
4
(28
)
0.
42
(0.
31
–0
.57
)**
Pr
ev
en
tio
n 
m
es
sa
ge
 
 
N
o
39
/1
08
(36
)
1
34
/1
08
(31
)
1
 
 
Ye
s
24
6/
67
1
(37
)
1.
06
(0.
68
–1
.66
)
24
4/
67
0
(36
)
1.
25
(0.
79
–1
.98
)
U
rg
en
cy
 
 
N
o
16
9/
46
3
(37
)
1
17
5/
46
3
(38
)
1
 
 
Ye
s
11
6/
31
6
(37
)
1.
07
(0.
79
–1
.45
)
10
3/
31
5
(33
)
0.
80
(0.
59
–1
.09
)
O
ve
ra
ll 
qu
al
ity
 
 
Lo
w
-q
ua
lit
y
11
3/
23
7
(48
)
1
10
4/
23
6
(44
)
1
 
 
H
ig
h-
qu
al
ity
17
2/
54
2
(32
)
0.
52
(0.
38
–0
.72
)**
17
4/
54
2
(32
)
0.
59
(0.
43
–0
.82
)**
N
ot
e:
 
M
od
el
s c
on
tro
l f
or
 c
hi
ld
’s
 se
x
, 
ch
ild
’s
 a
ge
, c
hi
ld
’s
 ra
ce
/e
th
ni
ci
ty
,
 
pa
re
nt
’s
 e
du
ca
tio
na
l a
tta
in
m
en
t, 
an
d 
an
nu
al
 h
ou
se
ho
ld
 in
co
m
e.
H
PV
: 
hu
m
an
 p
ap
ill
om
av
iru
s. 
O
R:
 o
dd
s r
at
io
. C
I: 
co
nf
id
en
ce
 in
te
rv
al
.
a O
dd
s o
f r
ef
us
in
g 
H
PV
 v
ac
ci
ne
, a
m
on
g 
th
os
e 
w
ho
 re
ce
iv
ed
 a
 p
ro
v
id
er
 re
co
m
m
en
da
tio
n 
(n=
77
9).
 A
na
lys
es 
ex
cl
ud
e 
re
sp
on
de
nt
s (
n
=
2) 
wh
o d
id 
no
t p
rov
id
e 
da
ta
 o
n 
H
PV
 v
ac
ci
ne
 re
fu
sa
l.
b O
dd
s o
f d
el
ay
in
g 
H
PV
 v
ac
ci
ne
, a
m
on
g 
th
os
e 
w
ho
 re
ce
iv
ed
 a
 p
ro
v
id
er
 re
co
m
m
en
da
tio
n 
(n=
77
8).
 A
na
lys
es 
ex
cl
ud
e 
re
sp
on
de
nt
s (
n
=
3) 
wh
o d
id 
no
t p
rov
id
e 
da
ta
 o
n 
H
PV
 v
ac
ci
ne
 d
el
ay
.
*
p 
<
 0
.0
5,
*
*
p 
<
 0
.0
1
Vaccine. Author manuscript; available in PMC 2017 February 24.
